日常关联交易对上市公司的影响：深圳瑞华泰薄膜科技股份有限公司（以 下简称"公司"或"瑞华泰"）2025 年度预计的日常关联交易是基于公司正常 生产经营需要，以市场价格为定价依据，交易定价公平、合理，不会影响公司的 独立性，不存在损害公司和全体股东利益的情形，不会对关联人形成较大的依赖。 一、日常关联交易基本情况 （一）日常关联交易履行的审议程序 公司于 2025 年 3 月 17 日召开了第二届董事会独立董事第三次专门会议，审 议了《关于公司 2025 年度日常关联交易预计的议案》，全体独立董事一致同意 本次关联交易事项，并同意将该议案提交至董事会审议。2025 年 3 月 20 日，召 开了第二届董事会第二十七次会议和第二届监事会第十八次会议，审议通过了上 述议案，公司董事会在审议该议案时，关联董事汤昌丹先生回避表决，出席会议 的非关联董事一致同意该议案。公司监事会在审议该议案时，出席会议的监事一 致同意该议案。 | 证券代码：688323 | 证券简称：瑞华泰 | 公告编号：2025-014 | | --- | --- | --- | | 转债代码：118018 | 转债简称：瑞科转债 | | 深圳瑞华泰 ...

深圳瑞华泰薄膜科技股份有限公司 未来三年（2025-2027 年度）股东分红回报规划 为完善和健全深圳瑞华泰薄膜科技股份有限公司（以下简称"公司"）科学、 持续、稳定的分红决策和监督机制，积极回报投资者，引导投资者树立长期投资 和理性投资理念，根据《中华人民共和国公司法》《上市公司监管指引第 3 号—— 上市公司现金分红》《关于进一步落实上市公司现金分红有关事项的通知》及《深 圳瑞华泰薄膜科技股份有限公司公司章程》（以下简称"《公司章程》"）等相 关法律法规的规定，结合公司实际情况和发展目标，公司董事会制定了《深圳瑞 华泰薄膜科技股份有限公司未来三年（2025－2027 年度）股东分红回报规划》（以 下简称"本规划"），具体内容如下： 一、公司制定未来三年股东回报规划的考虑因素 公司将着眼于长远和可持续发展，在综合考虑行业发展趋势、公司实际经营 状况、发展目标、股东意愿和要求、社会资金成本和外部融资环境等因素的基础 上，建立持续、稳定、科学的投资者回报规划，并对股利分配作出制度性安排， 以保证股利分配政策的连续性和稳定性。 二、公司制定未来三年股东回报规划的原则 公司的股东回报规划应充分考虑和听取独立董事、股 ...

| 证券代码：688323 | 证券简称：瑞华泰 | 公告编号：2025-017 | | --- | --- | --- | | 转债代码：118018 | 转债简称：瑞科转债 | | 股东大会召开日期：2025年4月11日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 （二） 股东大会召集人：董事会 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 （四） 现场会议召开的日期、时间和地点 召开日期时间：2025 年 4 月 11 日 14 点 00 分 召开地点：深圳市宝安区松岗街道办华美工业园深圳瑞华泰薄膜科技股份有 限公司会议室 （五） 网络投票的系统、起止日期和投票时间。 深圳瑞华泰薄膜科技股份有限公司 关于召开 2024 年年度股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东大会类型和届次 2024 年年度股东大会 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自 20 ...

| | | 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 深圳瑞华泰薄膜科技股份有限公司 第二届监事会第十八次会议决议公告 经与会监事充分讨论，本次会议以记名投票方式审议通过了如下议案： （一） 审议通过《关于公司 2024 年度监事会工作报告的议案》 公司监事会认为：2024 年，公司监事会按照《公司法》《中华人民共和国证 券法》《上海证券交易所科创板股票上市规则》等法律、法规及规范性文件，并 依照《公司章程》和公司《监事会议事规则》的规定，认真、独立地履行监督检 查职责。围绕公司合规运营、财务状况及董事和高级管理人员职责履行等方面积 极开展相关工作，为公司的规范运作和健康发展提供了有力保障。 深圳瑞华泰薄膜科技股份有限公司（以下简称"公司"）第二届监事会第十 八次会议于 2025 年 3 月 10 日以电子邮件方式发出了本次会议的召开通知，于 2025 年 3 月 20 日以现场方式召开。本次会议应出席的监事 3 名，实际出席的监 事 3 名。会议的召集、召开和表决程序符合《中华人民共和国公司 ...

| 证券代码：688323 | 证券简称：瑞华泰 | 公告编号：2025-007 | | --- | --- | --- | | 转债代码：118018 | 转债简称：瑞科转债 | | 深圳瑞华泰薄膜科技股份有限公司 第二届董事会第二十七次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 深圳瑞华泰薄膜科技股份有限公司（以下简称"公司"）第二届董事会第二 十七次会议于 2025 年 3 月 10 日以电子邮件方式发出了本次会议的召开通知，于 2025 年 3 月 20 日以现场及通讯方式召开。本次会议应出席的董事 7 名，实际出 席的董事 7 名。会议的召集、召开和表决程序符合《中华人民共和国公司法》（以 下简称"《公司法》"）等法律、行政法规、规范性文件以及《深圳瑞华泰薄膜科 技股份有限公司章程》（以下简称"《公司章程》"）等规定。 二、董事会会议审议情况 经与会董事充分讨论，本次会议以记名投票方式审议通过了如下议案： （一） 审议通过《关于公司 2024 年度董事会工作报告的议案》 ...

Financial Performance - The company reported no cash dividends, stock bonuses, or capital reserve transfers for the 2024 profit distribution plan, which was approved by the board[7]. - The company has not achieved profitability since its listing, indicating ongoing financial challenges[5]. - A standard unqualified audit report was issued by DaXin Accounting Firm, ensuring the accuracy of the financial statements[6]. - The company's operating revenue for 2024 reached RMB 339,054,434.45, representing a 22.88% increase compared to RMB 275,928,076.04 in 2023[22]. - The net profit attributable to shareholders of the listed company was a loss of RMB 57,274,907.69 in 2024, compared to a loss of RMB 19,603,013.62 in 2023[22]. - The net cash flow from operating activities increased significantly by 125.20% to RMB 137,523,874.31 in 2024, up from RMB 61,066,979.78 in 2023[22]. - Total assets as of the end of 2024 amounted to RMB 2,563,947,151.17, reflecting a 4.76% increase from RMB 2,447,368,795.73 at the end of 2023[22]. - The net assets attributable to shareholders decreased by 5.63% to RMB 943,121,144.92 at the end of 2024, down from RMB 999,364,018.07 at the end of 2023[22]. - The company reported a revenue of RMB 336,914,126.10 after excluding non-main business income, which is a 22.10% increase from the previous year[22]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was a loss of RMB 57,628,224.39 in 2024, compared to a loss of RMB 21,888,027.48 in 2023[22]. - The basic and diluted earnings per share for 2024 are both -0.32 CNY, a decrease from -0.11 CNY in 2023[23]. - The net profit attributable to shareholders for the reporting period is -57.27 million CNY, an increase in loss of 37.67 million CNY compared to the previous year[24]. - The weighted average return on equity decreased by 3.97 percentage points to -5.90% in 2024 from -1.93% in 2023[23]. - The gross profit margin decreased, and the increase in depreciation and interest expenses contributed to the losses[93]. Operational Risks and Compliance - The company has detailed various operational risks in the report, which investors should be aware of[5]. - There are no non-operational fund occupations by controlling shareholders or related parties, ensuring financial integrity[9]. - The company has not violated decision-making procedures for external guarantees, maintaining compliance with regulations[10]. - The report includes a forward-looking statement risk declaration, cautioning investors about potential uncertainties in future plans[8]. - The company operates in a competitive market with larger international players, which may affect its market share and operational performance if competition intensifies[100]. - The company does not have a controlling shareholder, which may lead to decision-making challenges and potential risks in business operations[102]. - The company is exposed to risks related to the repayment of convertible bonds if its financial condition deteriorates or if external financing becomes restricted[105]. Research and Development - The company is focusing on the development of new products and technologies in the polyimide film sector, particularly for flexible OLED displays[17]. - The company plans to expand its market presence and explore potential mergers and acquisitions to enhance growth opportunities[17]. - The management remains optimistic about future performance despite the current financial losses, aiming for improved profitability in the upcoming fiscal periods[17]. - Research and development expenses accounted for 9.95% of operating revenue, down from 11.67% in 2023[23]. - The company achieved a total R&D investment of ¥33,733,042.13, representing a 4.78% increase compared to the previous year[72]. - The company obtained 4 new patents during the reporting period, bringing the total to 37 patents, including 30 invention patents[70]. - The company is currently developing a high-performance PI film with a target thickness of 100μm and a thermal conductivity of over 1500W/m.K[75]. - The company is researching high thermal conductivity PI films, targeting a thermal conductivity greater than 0.6W/mK to meet increasing demands in semiconductor packaging[76]. - The company has a total of 11 ongoing R&D projects, focusing on various applications including flexible electronics and high-frequency communication[75]. Market and Product Development - The company is focusing on expanding markets for 5G/6G PI films, electronic substrates, and high thermal conductivity PI films[40]. - The company has entered the supply chains of well-known manufacturers such as Shengyi Technology and Unimicron, indicating strong market acceptance of its electronic PI films[46]. - The flexible display CPI film, with a foldability exceeding 200,000 times, is in the testing phase for terminal brand manufacturers, aiming to fill a domestic gap in flexible display applications[50]. - The company is committed to advancing technology and product development in the clean energy sector, particularly for applications in electric vehicles and wind energy[161]. - The company plans to focus on the development of new products for high-frequency and high-speed flexible electronic substrates in response to the accelerating 6G technology research and AI computing demand[158]. - New product launches include low-dielectric substrates for 5G/6G, high thermal conductivity PI films, and functional PI products for electric vehicles and OLED applications[163]. Governance and Management - The company has a comprehensive governance structure in place, with all board members present at the meeting[6]. - The financial report is signed and sealed by the company's legal representative and accounting personnel, affirming its authenticity[10]. - The company emphasizes the importance of maintaining a robust governance structure to ensure compliance with legal and regulatory requirements, enhancing decision-making fairness[167]. - The company held two shareholder meetings during the reporting period, with all resolutions passed and no resolutions rejected[169]. - The company’s governance structure remains compliant with relevant laws and regulations, ensuring the legality and effectiveness of shareholder meetings[169]. - The company is in the process of preparing for the nomination of new candidates for the board and supervisory positions, indicating a focus on future leadership continuity[176]. - The total remuneration for the chairman, Song Shuqing, was reported as 0.00 million, while the general manager, Tang Changdan, received 77.38 million[173]. - The company has maintained a stable leadership structure with no significant turnover among key executives during the reporting period[181]. Financial Strategy and Investments - The company plans to increase its production capacity of high-performance PI films by 1,600 tons, which is a significant increase compared to existing capacity[104]. - The company plans to implement a profit distribution proposal for 2023, reflecting a commitment to shareholder returns[189]. - The company will adopt a mixed financing strategy to support large-scale project investments while monitoring long-term government bond opportunities to reduce financial costs[165]. - The company is strategically positioning itself in upstream specialty monomers to ensure timely supply of raw materials and mitigate supply chain risks[165]. - The company has invested a total of 5,956.62 million RMB in the reporting period, representing a 42.09% increase compared to the previous year[149]. - The company reported a total revenue of 1.2 billion RMB for the fiscal year 2024, representing a year-over-year growth of 15%[179]. - The company has provided a revenue guidance of 1.5 billion RMB for the next fiscal year, which reflects an expected growth of 25%[179]. - The company plans to invest in high-speed communication flexible substrates and functional polyimide films for rail transit through its wholly-owned subsidiary[164].

| 证券代码：688323 | 证券简称：瑞华泰 | 公告编号：2025-013 | | --- | --- | --- | | 转债代码：118018 | 转债简称：瑞科转债 | | 深圳瑞华泰薄膜科技股份有限公司 关于 2024 年度利润分配预案的公告 经大信会计师事务所（特殊普通合伙）审计，2024 年度公司合并口径实现 归属于公司普通股股东净利润为人民币-5,727.49 万元，截至 2024 年 12 月 31 日， 母公司期末可供分配利润为人民币 11,267.62 万元。 根据《中华人民共和国公司法》《深圳瑞华泰薄膜科技股份有限公司章程》 的相关规定，鉴于公司 2024 年度亏损，结合公司实际经营和长期资金发展需求， 为实现公司平稳运营、健康发展，同时更好地维护全体股东的长远利益，公司 2024 年度不派发现金红利，不进行资本公积转增股本，不送红股。 本次利润分配方案尚需提交公司股东大会审议。 二、公司履行的决策程序 1 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 深圳瑞华泰薄膜科技股份有 ...

Financial Performance - The total operating revenue for 2024 reached CNY 339.05 million, representing a year-on-year increase of 22.88%[3] - The net profit attributable to the parent company was CNY -57.27 million, an increase in loss of CNY 37.67 million compared to the previous year[6] - The net profit attributable to the parent company after deducting non-recurring gains and losses was CNY -57.67 million, an increase in loss of CNY 35.78 million year-on-year[6] - The basic earnings per share were CNY -0.32, a decline compared to CNY -0.11 in the previous year[3] - The weighted average return on net assets was -5.90%, a decrease of 3.97 percentage points from the previous year[3] Assets and Equity - Total assets at the end of the reporting period were CNY 2,563.95 million, an increase of 4.76% from the beginning of the period[6] - Equity attributable to the parent company decreased by 5.63% to CNY 943.12 million compared to the beginning of the period[6] Operational Challenges - The company faced pressure on short-term performance due to global economic recovery challenges and intensified competition[6] - Management expenses and financial expenses increased by 28.38% and 137.03% respectively due to depreciation and interest expenses from the new production project[7] Strategic Focus - The company is focusing on high-performance polyimide film R&D, production, and sales while adjusting product structure and expanding new product application markets[6]

国信证券股份有限公司（以下简称"国信证券"或"保荐机构"）作为深圳 瑞华泰薄膜科技股份有限公司（以下简称"瑞华泰"或"公司"）首次公开发行 股票和向不特定对象发行可转换公司债券的保荐机构，根据《上海证券交易所科 创板股票上市规则》《上海证券交易所上市公司自律监管指引第 11 号——持续 督导》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》等 有关法律、法规和规范性文件的要求，对瑞华泰自 2024 年 1 月 1 日至本次现场 检查期间（以下简称"检查期"）的规范运作情况进行了现场检查，就现场检查 的有关情况报告如下： 一、本次现场检查的基本情况 国信证券股份有限公司 关于深圳瑞华泰薄膜科技股份有限公司 2024 年度持续督导工作现场检查报告 上海证券交易所： 2025 年 2 月 5 日至 2 月 6 日，国信证券现场检查人员郭振国通过查阅资料、 实地调研等方式对瑞华泰检查期的有关情况进行了现场检查，检查的内容包括： （一）公司治理和内部控制情况；（二）信息披露情况；（三）公司的独立性以 及与主要股东及其他关联方资金往来情况；（四）募集资金使用情况；（五）关 联交易、对外担保、重大对外投资 ...

深圳瑞华泰薄膜科技股份有限公司（以下简称"公司"）第二届董事会、监 事会任期于 2025 年 2 月 10 日届满。鉴于公司新一届董事会、监事会的董事、监 事候选人的提名工作尚在筹备中，为保证公司董事会、监事会相关工作的连续性， 公司第二届董事会、监事会将延期换届，董事会各专门委员会、高级管理人员及 董事会聘任的其他人员的任期亦将相应顺延。 在公司新一届董事会、监事会换届选举完成之前，公司第二届董事会和监事 会全体成员、董事会各专门委员会成员及高级管理人员将按照相关法律法规及 《深圳瑞华泰薄膜科技股份有限公司章程》等的规定，继续履行相应的义务和职 责。 公司董事会与监事会延期换届不会影响公司的正常运营。公司亦将积极推进 相关工作，尽快完成董事会与监事会的换届选举工作，并及时履行相应的信息披 露义务。 | 证券代码：688323 证券简称：瑞华泰 | 公告编号：2025-005 | | --- | --- | | 转债代码：118018 转债简称：瑞科转债 | | 深圳瑞华泰薄膜科技股份有限公司 关于董事会、监事会延期换届的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大 ...